Cargando…

Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate‑1 risk patients with myelodysplastic syndromes

Vascular endothelial growth factors (VEGFs) are angiogenic factors playing a key role in tumor development. VEGFs are produced by different normal and tumor cells, including platelets, lymphocytes and mononuclear cells of peripheral blood. VEGF (VEGF-A, VEGF-C and VEGF-D) and VEGFR (VEGFR1, VEGFR2 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalitin, Nikolay, Dudina, Galina, Kostritsa, Natalia, Sivirinova, Anastasiya, Karamysheva, Aida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932006/ https://www.ncbi.nlm.nih.gov/pubmed/36817042 http://dx.doi.org/10.3892/ol.2023.13681

Ejemplares similares

Prognostic Markers of Myelodysplastic Syndromes
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis
por: Kilvaer, Thomas K., et al.
Publicado: (2010)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Prognostic value and association of Lauren classification with VEGF and VEGFR-2 expression in gastric cancer
por: Li, Xiayi, et al.
Publicado: (2019)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

Regulatory T Cells and Profile of FOXP3 Isoforms Expression in Peripheral Blood of Patients with Myelodysplastic Syndromes
por: Dudina, Galina A., et al.
Publicado: (2018)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome
por: Sjöström, S., et al.
Publicado: (2010)

Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
por: Yang, Gui-Li, et al.
Publicado: (2018)

The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
por: Mabeta, Peace, et al.
Publicado: (2022)

Structure-Based Design of Peptides Targeting VEGF/VEGFRs
por: Di Stasi, Rossella, et al.
Publicado: (2023)

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer
por: Zajkowska, Monika, et al.
Publicado: (2018)

Prognostic Roles of Cross-Talk between Peritumoral Hepatocytes and Stromal Cells in Hepatocellular Carcinoma Involving Peritumoral VEGF-C, VEGFR-1 and VEGFR-3
por: Zhuang, Peng-Yuan, et al.
Publicado: (2013)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

The role of the VEGF-C/VEGFR-3 axis in cancer progression
por: Su, J-L, et al.
Publicado: (2007)

The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy
por: Chen, Jui-Chieh, et al.
Publicado: (2012)

Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
por: Li, Yu-Ling, et al.
Publicado: (2016)

VEGF-A splice variants bind VEGFRs with differential affinities
por: Mamer, Spencer B., et al.
Publicado: (2020)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
por: Bando, H, et al.
Publicado: (2005)

Diagnostic and Prognostic Power of Active DNA Demethylation Pathway Intermediates in Acute Myelogenous Leukemia and Myelodysplastic Syndromes
por: Skalska-Bugala, Aleksandra, et al.
Publicado: (2022)

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
por: Vicente, Alana, et al.
Publicado: (2020)

Diagnostics and Prognostication of Myelodysplastic Syndromes
por: Zini, Gina
Publicado: (2017)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer
por: D’Haene, Nicky, et al.
Publicado: (2018)

Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus)
por: Yao, Yuchen, et al.
Publicado: (2021)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome
por: Botezatu, Lacramioara, et al.
Publicado: (2016)

Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies
por: Meng, Qian, et al.
Publicado: (2016)

Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1
por: Eilken, Hanna M., et al.
Publicado: (2017)

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
por: Peach, Chloe J., et al.
Publicado: (2018)

Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis
por: Dai, Huihui, et al.
Publicado: (2020)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
por: Oliva, Esther N., et al.
Publicado: (2015)

The Evolving Landscape of Myelodysplastic Syndrome Prognostication
por: Shreve, Jacob, et al.
Publicado: (2020)

Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
por: Wang, Fei, et al.
Publicado: (2013)

Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
por: He, Rong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2tmji1t635bolps5km2kre22n